| For: | Eguchi Y, Mizuta T, Yasutake T, Hisatomi A, Iwakiri R, Ozaki I, Fujimoto K. High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol 2006; 12(4): 556-560 [PMID: 16489668 DOI: 10.3748/wjg.v12.i4.556] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i4/556.htm |
| Number | Citing Articles |
| 1 |
Takumi Kawaguchi, Yumiko Nagao, Michio Sata. Independent factors associated with altered plasma active ghrelin levels in HCV‐infected patients. Liver International 2013; 33(10) doi: 10.1111/liv.12235
|
| 2 |
Joanna Olszok, Anna Wyganowska, Joanna Tarabura-Dragon, Franciszek Mazur, Mariusz Nowak. Selected adipocytokines and their potential role in the control of the course
of chronic hepatitis B and C. Annales Academiae Medicae Silesiensis 2015; 69 doi: 10.18794/aams/23858
|
| 3 |
Udayakumar Navaneethan, Nyingi Kemmer, Guy W. Neff. Review: Predicting the probable outcome of treatment in HCV patients. Therapeutic Advances in Gastroenterology 2009; 2(5) doi: 10.1177/1756283X09339079
|
| 4 |
Toshihiko Mizuta. Can exercise be a new approach for chronic hepatitis C?. Hepatology Research 2011; 41(10) doi: 10.1111/j.1872-034X.2011.00885.x
|
| 5 |
Toshihiko Mizuta, Yasunori Kawaguchi, Yuichiro Eguchi, Hirokazu Takahashi, Keisuke Ario, Takumi Akiyama, Noriko Oza, Taiga Otsuka, Takuya Kuwashiro, Toru Yoshimura, Akitaka Hisatomi, Iwata Ozaki. Whole-Body Insulin Sensitivity Index Is a Highly Specific Predictive Marker for Virological Response to Peginterferon Plus Ribavirin Therapy in Chronic Hepatitis C Patients with Genotype 1b and High Viral Load. Digestive Diseases and Sciences 2010; 55(1) doi: 10.1007/s10620-008-0691-2
|
| 6 |
Ching-Sheng Hsu, Jia-Horng Kao. Insulin resistance, adipocytokines, and hepatitis C virus infection: A missing link?. Hepatology 2008; 47(2) doi: 10.1002/hep.22066
|
| 7 |
Ming-Ling Chang, Zinger Yang, Sien-Sing Yang. Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression. International Journal of Molecular Sciences 2020; 21(21) doi: 10.3390/ijms21218308
|
| 8 |
Ming-Ling Chang, Chia-Jung Kuo, Hsin-Chih Huang, Yin-Yi Chu, Cheng-Tang Chiu, Salvatore Petta. Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity. PLOS ONE 2016; 11(11) doi: 10.1371/journal.pone.0166712
|
| 9 |
Abdel-Rahman El-Zayadi. Hepatic steatosis: A benign disease or a silent killer. World Journal of Gastroenterology 2008; 14(26): 4120-4126 doi: 10.3748/wjg.14.4120
|
| 10 |
Nyingi Kemmer, Guy W. Neff. Managing chronic hepatitis C in the difficult‐to‐treat patient. Liver International 2007; 27(10) doi: 10.1111/j.1478-3231.2007.01613.x
|
| 11 |
Spilios Manolakopoulos, Sotirios Bethanis, Charis Liapi, Fotini Stripeli, Pantelis Sklavos, Alexandra Margeli, Aggeliki Christidou, Aggeliki Katsanika, Evangellos Vogiatzakis, Dimitrios Tzourmakliotis, Stamatios Theocharis. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study. BMC Gastroenterology 2007; 7(1) doi: 10.1186/1471-230X-7-17
|
| 12 |
N. V. Dhurandhar, D. Bailey, D. Thomas. Interaction of obesity and infections. Obesity Reviews 2015; 16(12) doi: 10.1111/obr.12320
|
| 13 |
F. Negro, S. Clément. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. Journal of Viral Hepatitis 2009; 16(10) doi: 10.1111/j.1365-2893.2009.01186.x
|
| 14 |
M Arai. The Effect on Gastric Emptying of Telaprevir-Based Triple Therapy for Chronic Hepatitis C Patients. Archives of Clinical Gastroenterology 2015; doi: 10.17352/2455-2283.000003
|
| 15 |
J. J. BLONSKY, S. A. HARRISON. Review article: nonalcoholic fatty liver disease and hepatitis C virus – partners in crime. Alimentary Pharmacology & Therapeutics 2008; 27(10) doi: 10.1111/j.1365-2036.2008.03672.x
|